Literature DB >> 29034433

Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis.

B Vijayalakshmi Ayyar1,2, M Zouhair Atassi3,4.   

Abstract

Myasthenia gravis (MG) is an autoimmune disease caused by sensitization of the immune system to self-antigens. We have previously shown that targeting MG-susceptible alleles can significantly inhibit proliferation of disease-specific T cells. In this work, we humanized a murine monoclonal antibody (mAb) LG11, capable of blocking MG-associated DQ beta 1 (DQB1) allele and reformatted it into single-chain fragment variable (scFv). A fully functional humanized scFv was obtained by optimizing variable domain orientations and linker lengths, along with the optimization of expression conditions and codons to suit Escherichia coli expression machinery. Characterization of humanized scFv (FL8) revealed that the reformatted scFv, despite recognizing the same epitope as the parent murine LG11 mAb, exhibited superior binding affinity (0.97 nM) compared to the LG11 mAb, towards the immunizing antigen (DQB1*0601/70-90) and was able to block the proliferation of T cells cultured from PBLs of MG-patients typed DQB1*0601. The scFv was also capable of binding a variant MG-associated allele (DQB1*0502/70-90) with moderate affinity (18.7 nM), a feature that was absent in the LG11. To our knowledge, this is the first report of humanizing a MG-associated human leukocyte antigen (HLA) scFv for preclinical studies.

Entities:  

Keywords:  Antibody engineering; Antibody humanization; Biacore; Expression optimization; Myasthenia gravis; scFv

Mesh:

Substances:

Year:  2017        PMID: 29034433     DOI: 10.1007/s00253-017-8557-1

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  3 in total

1.  Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.

Authors:  Roberto Massa; Giulia Greco; Manuela Testi; Emanuele Rastelli; Chiara Terracciano; Erica Frezza; Matteo Garibaldi; Girolama A Marfia; Franco Locatelli; Nicola B Mercuri; Eugenio Pompeo; Giovanni Antonini; Marco Andreani
Journal:  J Neurol       Date:  2019-02-11       Impact factor: 4.849

2.  Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm.

Authors:  İlkay Koçer; Emily C Cox; Matthew P DeLisa; Eda Çelik
Journal:  Biotechnol Prog       Date:  2020-11-20

Review 3.  New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.

Authors:  Ruksana Huda
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.